9 results on '"Ghorbanihaghjo, Amir"'
Search Results
2. Role of phosphor and GAS-6 in inflammation in hemodialysis patients in Tabriz, Iran
- Author
-
Halaj Zadeh, Jamal, Ghorbanihaghjo, Amir, Argani, Hassan, Valizadeh, Shahnam, Halaj, Najat, Vatankhah, Amirmansour, Aghdam, Hakimeh Rezaei, and Dastmalchi, Siavoush
- Subjects
Interleukin 6 (IL-6) ,High Sensitivity C-Reactive Protein ,lcsh:R5-920 ,Hemodialysis ,610 Medical sciences ,Medicine ,lcsh:Medicine (General) ,Growth Arrest-Specific 6 (GAS-6) - Abstract
BACKGROUND: Inflammation is recognized in up to 50% of chronic kidney disease (CKD) patients, being a common feature of advanced renal disease and crucial mediator of vascular calcification which may be relevant in CKD. This study was aimed at evaluating the role of Growth arrest–specific 6 (Plasma GAS-6) and mineral metabolism abnormalities in hemodialysis patients. METHODS: We enrolled a total of 92 adults including 46 (28 males and 18 females) clinically stable hemodialysis patients (HD) and 46 (23 males and 23 females) patients with normal kidney as control group. Plasma GAS-6, interleukin 6 (IL-6), and high sensitivity C-reactive protein (hsCRP) concentration and biochemical alteration were quantified; as biochemical factors, GAS-6, interleukin 6(IL-6), and high-sensitivity C-reactive protein (hsCRP) levels were determined by standard methods. RESULTS: Levels of GAS-6 were significantly increased in hemodialysis (HD) patients compared with normal controls (P < 0.001). In HD patients, IL-6, and hsCRP levels were increased compared with controls (P < 0.001). The levels of GAS-6 were directly associated with IL-6 (r = 0.560, P < 0.001) in HD patients. No significant correlation was found between hsCRP and GAS-6 levels in HD patients (r = 0.05, P = 0.742). Multiple regression analysis demonstrated that serum P was independently associated with hsCRP and GAS-6 independently associated with IL-6. CONCLUSIONS: Elevated serum P and GAS-6 might play a role in the development of inflammation in CKD patients. Although our study shows that GAS-6 is directly associated with IL-6 and phosphor with hsCRP, their direct role in vascular calcification and type of their relationships need further studies in the future., Journal of Analytical Research in Clinical Medicine; EISSN
- Published
- 2014
- Full Text
- View/download PDF
3. Growth Arrest-specific 6 Protein and Matrix Gla Protein in Hemodialysis Patients.
- Author
-
Hallajzadeh, Jamal, Ghorbanihaghjo, Amir, Argani, Hassan, Dastmalchi, Siavoush, and Rashtchizadeh, Nadereh
- Subjects
- *
HEMODIALYSIS patients , *BLOOD filtration , *KIDNEY disease treatments , *BLOOD plasma , *MEDICAL records - Abstract
Introduction. Plasma protein growth arrest-specific 6 (GAS6) and matrix Gla protein (MGP) are crucial mediators of vascular calcification and are involved in the development of vascular complications in chronic kidney diseases. This study was set out to investigate the relationship between plasma GAS6 levels and MGP in patients with end-stage renal disease on maintenance hemodialysis. Materials and Methods. Forty-six hemodialysis and 46 healthy individuals with normal kidneys were recruited. Plasma GAS6 and MGP concentrations and related biochemical factors were quantified as well as collection of data on clinical characteristics. Results. Plasma GAS6 levels were significantly higher in the hemodialysis patients as compared with the control group (763.52 ± 187.91 pg/mL versus 421.63 ± 189.91 pg/mL, P < .001). Plasma MGP concentration was significantly lower in the hemodialysis patients than the control group (52.35 ± 12.35 ng/ mL versus 6.60 ± 19.54 ng/mL, P < .001). The levels of GAS6 were inversely associated with MGP (r = -0.341, P = .02) in the hemodialysis patients. Conclusions. Increased GAS6 and decreased MGP levels in hemodialysis patients, as mediators of induction or prevention of vascular calcification, and their inverse correlation may suggest that there might be a role in increased calcification process in hemodialysis patients or only as a secondary phenomenon of advanced kidney failure. Their direct role on vascular calcification needs further studies in the future. [ABSTRACT FROM AUTHOR]
- Published
- 2015
4. Relationship Between Vitamin D Receptor Gene FokI and ApaI Polymorphisms and Serum Levels of Fetuin-A, Vitamin D, and Parathyroid Hormone in Patients on Hemodialysis.
- Author
-
Ghorbanihaghjo, Amir, Argani, Hassan, Samadi, Nasar, Valizadeh, Shahnam, Halajzadeh, Jamal, Yousefi, Bahman, and Rashtchizadeh, Nadereh
- Subjects
- *
ALPHA fetoproteins , *PHYSIOLOGICAL effects of vitamin D , *PARATHYROID hormone-related protein , *PARATHYROID hormone , *CARDIOVASCULAR disease treatment , *HEMODIALYSIS facilities - Abstract
Introduction. Low fetuin-A and 1,25-hydroxyvitamin D3 (vitamin D) levels accompanied with high intact parathyroid hormone (PTH) contents are associated with cardiovascular disease in dialysis patients. The aim of present study was to evaluate the relationship between vitamin D receptor (VDR) gene FokI and ApaI polymorphisms with serum levels of fetuin-A, vitamin D, and intact PTH in hemodialysis patients. Materials and Methods. Serum was obtained from 46 stable chronic hemodialysis patients and 43 healthy controls. Serum levels of intact PTH, fetuin-A, vitamin D, calcium, and phosphorus were measured. Genotyping of the VDR gene was performed using standard methods. Results. Serum fetuin-A and vitamin D levels were significantly lower, whereas serum levels of PTH, calcium, and Phosphorus were higher in the hemodialysis patients than in the healthy controls. The FokI genotypes were more frequent in the hemodialysis patients than the control group (P = .004). With respect to FokI genotypes, intact PTH level was higher among the hemodialysis patients compared to the controls (P = .02). In contrast, vitamin D level was lower in the hemodialysis patients with ApaI genotypes compared to the control group (P = .04). Conclusions. Our study shows that increased serum level of PTH and decreased fetuin-A and vitamin D levels may increase susceptibility of atherosclerosis in patients with hemodialysis through VDR gene FokI and ApaI polymorphisms. [ABSTRACT FROM AUTHOR]
- Published
- 2014
5. Serum Receptor Activator of Nuclear Factor-κ B Ligand, Osteoprotegrin, and Intact Parathyroid Hormone in Hemodialysis and Renal Transplant Patients.
- Author
-
Rashtchizadeh, Nadereh, Ghorbanihaghjo, Amir, Argani, Hassan, Mahmoudi Meimand, Saeed, Safa, Javid, Vatankhahan, Hamidreza, and Shahidi, Maryam
- Abstract
Serum receptor activator of nuclear factor-κ B ligand and osteoprotegrin are mediated to vascular calcification in the general population. Our knowledge is very sparse in hemodialysis and renal transplant patients. Receptor activator of nuclear factor-κ B ligand, osteoprotegrin, intact parathyroid hormone, calcium, and phosphorus were measured in blood samples of 45 hemodialysis and 45 age-matched renal transplant patients. Osteoprotegrin ( P = 0.001) and intact parathyroid hormone ( P = 0.001) levels in the hemodialysis patients were higher than the renal transplant recipients. Osteoprotegrin had positive correlation with duration of dialysis and age in the hemodialysis (r = 0.88, P = 0.001 and r = 0.34, P = 0.02, respectively) and renal transplant patients (r = 0.92, P = 0.001 and r = 0.46, P = 0.001, respectively). Hemodialysis patients have higher osteoprotegrin levels than the renal transplant recipients. It may act as a protective factor for renal osteodystrophy or only as a secondary phenomenon of advanced renal failure. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
6. Paraoxonase Enzyme Activity Is Enhanced by Zinc Supplementation in Hemodialysis Patients.
- Author
-
Rahimi-Ardabili, Babak, Argani, Hassan, Ghorbanihaghjo, Amir, Rashtchizadeh, Nadereh, Naghavi-Behzad, Mohammad, Ghorashi, Sona, and Nezami, Nariman
- Subjects
PARAOXONASE ,HEMODIALYSIS patients ,ZINC supplements ,ATHEROSCLEROSIS risk factors ,CARDIOVASCULAR disease related mortality ,RANDOMIZED controlled trials ,SPECTROPHOTOMETRY ,PLACEBOS - Abstract
Background and Aims: Patients on maintenance hemodialysis (HD) face an increased risk of atherosclerosis, a crucial problem and the leading cause of cardiovascular morbidity and mortality. This study was designed to evaluate the effects of zinc supplementation on paraoxonase (PON) enzyme activity in patients on HD. Methods: This double-blind randomized controlled trial was conducted from June 2005 to June 2007. Sixty HD patients were enrolled and divided into two groups: treatment (case) and control. The treatment and control groups were treated with 100 mg/day zinc or placebo, respectively, for 2 months. Serum zinc concentration was measured by atomic absorption spectrophotometry. PON activity was evaluated by spectrophotometric method. Lipid profile was determined using commercial kits, and apolipoprotein AI (Apo-AI) and B (Apo-B) levels were measured by commercial immunoturbidimetric kits. Results: In the case group, there was no significant change in the serum total cholesterol (TC), triglyceride (TG), low-density lipoprotein (LDL), and Apo-B levels, while the serum levels of high-density lipoprotein (HDL), Apo-AI, and PON activity were significantly increased ( p = 0.02). In the control group, although significant increases were observed in the serum levels of TC, TG, and Apo-B ( p = 0.009, 0.019, and 0.001, respectively), the serum PON activity was significantly decreased ( p = 0.025) and the serum levels of HDL, LDL, and Apo-AI were not changed. At the end of intervention period, the serum level of Apo-AI and PON activity were significantly higher in the case group. Conclusions: Zinc supplementation increased both the activity of PON and the serum level of Apo-AI in the HD patients. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
7. Serum Fetuin-A and Pentraxin3 in hemodialysis and renal transplant patients
- Author
-
Argani, Hassan, Ghorbanihaghjo, Amir, Panahi, Ghodratollah, Rashtchizadeh, Nadereh, Safa, Javid, and Meimand, Saeed Mahmoudi
- Subjects
- *
ALPHA fetoproteins , *BLOOD proteins , *PENTRAXINS , *HEMODIALYSIS , *KIDNEY transplantation , *INFLAMMATION , *CALCIFICATION - Abstract
Abstract: Objective: The aim of the present study was to evaluate of Fetuin-A and Pentraxin3 (PTX3) as the main factors for vascular calcification and inflammation in hemodialysis (HD) and renal transplant (RT) patients. Method: Serum was obtained from 45 stable chronic HD patients and 44 stable RT recipients. Biochemical factors, intact Parathormone, high-sensitive C-reactive protein (hsCRP), Fetuin-A and PTX3 levels were determined by standard methods. Results: In the RT recipients PTX3 level was significantly higher than the HD patients [5.78(1.09–20.36) ng/mL vs. 1.65(0.24–7.89) ng/mL, p≤0.001]. Serum Fetuin-A concentration was significantly higher in the HD compared to RT group [43.39(27.75–81.48) ng/mL vs. 38.76(22.26–89.07) ng/mL, p=0.020]. hsCRP level was also higher in the HD than the RT group [2.90(0.1–8.50) mg/L vs. 1.1(0.1–7.9) mg/L, p=0.003]. Conclusion: Although our study shows that serum PTX3 is increased and Fetuin-A is decreased after successful RT, their direct role on atherosclerosis needs further studies in the future. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
8. Effect of nandrolone decanonate on paraoxonase activity in hemodialysis patients
- Author
-
Ghorbanihaghjo, Amir, Argani, Hassan, Rahbaninoubar, Mohammad, and Rashtchizadeh, Nadereh
- Subjects
- *
PATIENTS , *BLOOD filtration , *DIALYSIS (Chemistry) , *THERAPEUTICS - Abstract
Abstract: Objectives: : This study was designed to determine the effect of nandrolone decanonate (ND) on HDL-C, apolipoproteins and paraoxonase (PON) activity in stable hemodialysis patients. Design and methods: : 64 hemodialysis patients were treated with ND at a dose of 100 mg/I.M./week for 4 months. HDL-C, Apo-AI, Apo B, concentrations and PON activity were measured before and after 2 and 4 months of treatment as well as 2 months after withdrawing the treatment. Results: : After 4 months of treatment, an elevation in the serum levels of Apo B (P < 0.0001) and a marked decrease in the concentration of HDL-C (P < 0.0001), Apo-AI (P < 0.0001) and PON activity (P < 0.0001) were found. A significant correlation between PON and both Apo-AI (r = 0.270, P < 0.04) and HDL-C (r = 0.455, P < 0.0001) and also between HDL-C and Apo-AI (r = 0.305, P < 0.02) were found. Conclusion: : Results revealed the adverse effects of ND on apolipoprotein levels in our study population. It is possible that ND reduces PON activity mostly by reducing both the HDL-C and Apo-AI levels. [Copyright &y& Elsevier]
- Published
- 2005
- Full Text
- View/download PDF
9. Effect of Nandrolone Decanoate on Serum Lipoprotein (a) and its isoforms in hemodialysis patients.
- Author
-
Ghorbanihaghjo, Amir, Argani, Hassan, Rohbaninoubar, Mohammad, and Rashtchizadeh, Nadereh
- Subjects
- *
NANDROLONE , *HEMODIALYSIS , *MALNUTRITION , *LIPOPROTEINS , *HIGH density lipoproteins , *HEMOGLOBINS - Abstract
Malnutrition, anemia and increased atherosclerosis are the main causes of mortality in hemodialysis patients. Therapies designed to improve the disorders might therefore be expected to improve outcome. The effects of Nandrolone Decanoate (ND), in 64 stable hemodialysis patients, were studied with respect to the following parameters: nutritional status, hematological indexes, lipid profiles including serum levels of lipoprotein(a) [Lp(a)] in terms of differences in apolipoprotein(a) [apo(a)]. The patients were treated with ND at dose of 100 mg/I.M./week for 4 months. After 2 and 4 months of treatment the elevations in the serum levels of albumin (p < 0.0001), creatinine (p < 0.009), hemoglobin (p < 0.03), hematocrit (p < 0.03), cholesterol (p = 0.007) and triglyceride (p < 0.04) were noticed. Marked decrease in the concentration of high-density lipoprotein cholesterol (p = 0.007) and Lp(a) (p < 0.0001) were also found. These effects after 2 months of treatment withdrawal were relatively constant. By dividing patients according to the baseline Lp(a) levels and molecular weight of apo(a) isoform, it was noticed that the decrease in serum Lp(a) was significant in patients with high Lp(a) (> 30 mg/dl) than those of with low Lp(a) (< 30 mg/dl), irrespective of apo(a) molecular weight. It may be suggested that, ND has beneficial effect on nutritional status and treatment of anemia in hemodialysis patients. In spite the adverse effect of ND on lipid profile, it decreases Lp(a) mostly in patients with high serum Lp(a) preferently by the effect on apo(a) gene transcriptional activity. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.